MLchartDataset catalogue

Rovalpituzumab tesirine

Term · Oncology and biomedicine · MLC-T-ONC-016592

An antibody-drug conjugate (ADC) containing an antibody (SC16) directed against an as of yet undisclosed protein and conjugated to the cytotoxic agent D6.5, with potential antineoplastic activity. Upon administration, the antibody moiety of rovalpituzumab tesirine selectively binds to the target on tumor cell surfaces. Upon internalization, the D6.5 moiety is released and causes DNA damage, which may result in the inhibition of proliferation of tumor cells that overexpress this target.

Table 1. Record
IdentifierMLC-T-ONC-016592
FieldOncology and biomedicine
Synonymsantibody-drug conjugate SC16LD6.5; anti-SC16 ADC SC16LD6.5; Rova-T
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016592",
  "term": "Rovalpituzumab tesirine",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) containing an antibody (SC16) directed against an as of yet undisclosed protein and conjugated to the cytotoxic agent D6.5, with potential antineoplastic activity. Upon administration, the antibody moiety of rovalpituzumab tesirine selectively binds to the target on tumor cell surfaces. Upon internalization, the D6.5 moiety is released and causes DNA damage, which may result in the inhibition of proliferation of tumor cells that overexpress this target.",
  "synonyms": [
    "antibody-drug conjugate SC16LD6.5",
    "anti-SC16 ADC SC16LD6.5",
    "Rova-T"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rovalpituzumab-tesirine/"
}

Record 14,581 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.